Vector VestAdvertisement SPDR Advertisement
Home > Boards > US OTC > Biotechs >

PharmaCyte Biotech Inc. (PMCB)

Add PMCB Price Alert      Hide Sticky   Hide Intro
Moderator: No Moderator bulldurham, TopPenny, Peacefulwendy, TheBestInvest, PetePham, KitchenRat
Search This Board:
Last Post: 1/29/2015 3:14:17 PM - Followers: 513 - Board type: Free - Posts Today: 91

Welcome to PharmaCyte BioTech
FDA Grants Orphan Drug Designation to Nuvilex for Pancreatic Cancer Treatment

ThaiTECT ???????? 14 - Drug Development Part I : International Experiences

Nuvilex/Austrianova declared the winner of the 2014 Best Innovation Award

Encapsulation of Insulin Producing Cells for Diabetes Treatment Using 
Alginate and Cellulose Sulphate as Bioencapsulation Polymers

NUVILEX (NVLX)- The Next Great Biotech Story (VIDEO)


PharmaCyte Company Address
   PharmaCyte BioTech, Inc.
   Meadows Corporate Park I
   12510 Prosperity Dr., Suite #310
   Silver Spring, MD 20904-1643
   Phone:  (877) 958-7616 , (917) 595-2850
   Fax: (917) 595-2851

Market Value:
$162,381,784 a/o Oct 31, 2014

Shares Outstanding:
699,292.029 a/o Dec 15, 2014

Authorized Shares:
1,490,000,000 a/o Aug 26, 2014

529,206,849 a/o Aug 26, 2014

Short Selling Data

Short Interest: 8,450,144 a/o Aug 29, 2014

For more updated information please visit:

Transfer Agent:
Signature  Stock Transfer Inc. Plano TX  Ph # 972-612-4120

Investor Relations

Jamien Jones 
Blueprint Life Science Group 
Telephone: 415.375.3340 Ext. 103 


All News Releases:

All Information about Nuvilex:

What is Cell-in-a-Box®?

The Cell-in-a-Box® technology, developed by Austrianova, is a means to protect, isolate, storeand transport living cells. The proprietary technology can be used for a variety of purposes.
In healthcare, it facilitates the safe implantation of cells, holding them isolated from the immune system and allowing long term production of therapeutic molecules in patients. 
In biotechnology, the Cell-in-a-Box® technology protects cells in bioreactors and fermenters, while at the same time simplifying purification of bioproducts produced from the cells and reducing production cost. 
The technology can also be applied to probiotics, cosmetics and agriculture, environmental protection and monitoring, as well as forming the basis of a powerful research tool. 
The company’s proprietary cell packaging material, Gel8, used for the Cell-in-a-Box® technology, is derived from a naturally occurring material and is thus harmless to the environment, biologically inert and has been shown to be safe in humans. 

PharmaCyte Biotech is a clinical stage biotechnology company focused on developing and preparing to commercialize treatments for cancer and diabetes based upon a proprietary cellulose-based live cell encapsulation technology known as Cell-in-a-Box®. This unique and patented technology will be used as a platform upon which treatments for several types of cancer, including advanced, inoperable pancreatic cancer, and diabetes are being built. PharmaCyte Biotech's treatment for pancreatic cancer involves low doses of the well-known anticancer prodrug ifosfamide, together with encapsulated live cells, which convert ifosfamide into its active or "cancer-killing" form. These capsules are placed as close to the cancerous tumor as possible to enable the delivery of the highest levels of the cancer-killing drug at the source of the cancer. This "targeted chemotherapy" has proven remarkably effective in past clinical trials. In addition, PharmaCyte Biotech is working towards improving the quality of life for patients with advanced pancreatic cancer and on treatments for other types of solid cancerous tumors.


Austria Nova Demonstration Video


SMMG Radio Interview with COO Dr. Crabtree ~ 2013

Shareholder Update with CEO & COO via SMMG Interview ~ July 2014

The proprietary technology can be used for a variety of purposes.

In healthcare, it facilitates the safe implantation of cells, holding them isolated from the immune system and allowing long term production of therapeutic molecules in patients.

In biotechnology, the Cell-in-a-Box™ technology protects cells in bioreactors and fermenters, while at the same time simplifying purification of bioproducts produced from the cells and reducing production cost.

The technology can also be applied to probiotics, cosmetics and agriculture, environmental protection and monitoring, as well as forming the basis of a powerful research tool

Management Team:


Kenneth L. Waggoner, Chief Executive Officer and President:

Kenneth L. Waggoner has almost four decades of experience in management, business, operations and law.  Mr. Waggoner started his career as an attorney in private practice. Notably he was a senior partner with Brobeck, Phleger and Harrison, named one of the top two law firms worldwide that provide services to biotechnology clients including Chiron, Amgen, Biogen Idec, Sangamo, Ligand, DepoTech and many others.  He was the Managing Partner of Brobeck’s Los Angeles office.  Mr. Waggoner was also a member of the Executive Committee for almost ten years and on the Policy Committee for numerous years managing Brobeck’s worldwide operations with annual revenues in excess of $750,000,000.  While at Brobeck, Mr. Waggoner was the Co-Chairman of Brobeck’s world-wide Environmental Law Group.

Further highlights of Mr. Waggoner’s career include leadership and legal positions with several start-up companies during the last several years as well as working with Fortune 500 companies most of his professional career.  During his tenure with Chevron, Mr. Waggoner served as the Vice President and General Counsel of its Global Downstream operations where he was responsible for the overall management of legal services to the North American, Latin American, Europe and Asian Products Companies.  At Chevron he led a successful restructuring of the company’s international Legal Department following Chevron’s acquisition of Texaco.

Mr. Waggoner received his Juris Doctorate. with honors in 1973 from Loyola University School of Law in Los Angeles.


Gerald W. Crabtree, Ph.D. – Chief Operating Officer and Director:

Dr. Crabtree is the Company’s Chief Operating Officer.  Since 1985, Dr. Crabtree has been involved with various biopharmaceutical companies where he has alternatively supervised and coordinated the development of multiple drug candidates, prepared clinical protocols, investigator brochures, monographs, research and review articles and served as project manager for development of major oncologic agents.  He is a Member of the American Society of Clinical Oncology and also is a past member of research grant review committees for the National Institute of Health and the American Cancer Society.  Dr. Crabtree established and directed, from inception, a department that monitored and coordinated the development of oncologic and immunologic drugs from initial discovery through regulatory approval in a major pharmaceutical company and served as project manager for the development of the anticancer agent, Taxol®.

Dr. Crabtree received his Ph.D. in Biochemistry from the University of Alberta, Edmonton, Alberta, Canada and has published over 80 articles in peer-reviewed journals.  He is a National Cancer Institute of Canada Research Fellow.  In addition, he served as Department Head of Molecular Pharmacology for the Nucleic Acid Research Institute, and prior to that as Associate Professor of Medicine with the Roger Williams Cancer Center at Brown University.  Dr. Crabtree has also served as Director of Project Planning and Management (Oncology/Immunology) at Bristol-Myers Squibb and as Vice-President of Research and Development at ETEX Corporation.  Most recently, Dr. Crabtree served as Interim CEO of PhytoCeutica, Inc., where he assisted in preparation and review of FDA documents, clinical study protocols, investment acquisitions and contracts and business plans.

Walter H. Gunzburg – Chief Scientific Officer:

Prof. Walter H. Gunzburg is the co-founder, Chairman of the Board and Chief Technical Officer of Austrianova. As well as being a full Professor of Virology at the University of Vienna since 1996, he has had many years of experience in the biotech industry. He was a scientific advisor to the international vaccine company, Bavarian Nordic, from 1994-2001 and was involved in their IPO. He has also been an scientific advisor to the German biotech companies, Paktis and Liponova, as well as the U.S. biotech company, Tocagen Inc., all of which developed/are developing advanced medicinal treatments for cancer. He was also the Director of the Christian Doppler Laboratory for Gene Therapeutic Vector Development from 2003-2011. Currently, he is a board member of ViruSure, a virus and prion testing company located in Vienna that he cofounded.

Prof. Gunzburg has been actively involved in European ethics and regulatory affairs in the fields of cell and gene therapy as well as xenotransplantation for many years. He was a member of the German Medical Association's Central Commission for Somatic Gene Therapy. He has also interacted with a number of regulatory agencies including the US FDA, EMA, TGA, HSA and Thai-FDA and was on the review panel for the Paul Ehrlich Institute, Langen, Germany. Prof. Gunzburg continues to be an active researcher and has published more than 130 peer-reviewed publications in international scientific and medical journals such as NatureThe Lancet,Proceedings of the National Academy of Sciences USA and Cancer Research as well as co-authoring the first German language textbook on gene therapy. He is also a member of the editorial board of a number of international cell and gene therapy journals including Trends in Molecular Medicine, and continues to be an active reviewer for many top tier journals as well as grant funding agencies.

Dr. Matthias Lohr as Chairman of Scientific Advisory Board:

Matthias Löhr was appointed professor of gastroenterology & hepatology at Karolinska Institutet in 2007, incoming from the Univ. Heidelberg/dkfz. From the times of his MD thesis through PhD and lateron, he concentrated on several aspects of the pancreas, both in clinical medicine, translational and basic sciences. He is heading the Pancreas Research Team at Gastrocentrum and leading the KICancer Diagnose-related network for HPB tumors. For hte European Gastroenterologists (UEG), he is sitting in several committees at the EU in Brussels. He is also leading the Pancreas 2000 program, an educational program for future pancreatologists in Europe.

Stock Chart
Company Info
Recent News
Filings and Disclosure
Short Sales
Insider Disclosure
Research Reports
Historical Prices
Interactive Chart
Basic Chart
Basic Tech. Analysis
Press Releases
Company Profile
Key Statistics
Major Holders
Insider Transactions
Insider Roster
Income Statement
Balance Sheet
Cash Flow
Market Watch
OTC Short Report




  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
Current Price
Bid Ask Day's Range
NVLX News: Current Report Filing (8-k) 01/09/2015 11:34:14 AM
NVLX News: Nuvilex Announces Name Change to PharmaCyte Biotech 01/07/2015 09:30:00 AM
NVLX News: Nuvilex to Attend 2015 Gastrointestinal Cancers Symposium in San Francisco, January 15-17, 2015 01/06/2015 09:30:00 AM
NVLX News: FDA Grants Orphan Drug Designation to Nuvilex for Pancreatic Cancer Treatment 12/22/2014 08:30:00 AM
NVLX News: Nuvilex’s Partner Austrianova Successfully Completes First Live-Cell Encapsulation in New Facility 12/18/2014 09:30:00 AM
News News Alert: PharmaCyte Biotech's Partner Austrianova Opens New Facilities in Singapore 01/29/2015 09:00:00 AM
#31049  Sticky Note $PMCB Where Do Human Trials Start? PetePham 01/29/15 02:48:49 PM
#30720  Sticky Note PharmaCyte Biotech's Expanded Follow-up Study on Malignant Ascites bulldurham 01/26/15 09:26:54 AM
#29729  Sticky Note FDA approval for ODD....Anne Simpson and UTA licensing efood125 01/11/15 09:48:16 AM
#18112  Sticky Note EVERYONE please keep your posts on-topic. The topic IH Geek [Dave] 03/14/14 12:28:20 PM
#31058   I have read that before Alydyr. You have avobill 01/29/15 03:23:59 PM
#31057   Darn right Bill. I will sticky this Mice PetePham 01/29/15 03:14:17 PM
#31056   How can anyone not root for a company avobill 01/29/15 03:10:01 PM
#31055   Where does the research money come from if trently 01/29/15 03:09:14 PM
#31053   Thanks for your input... I want yeahright231 01/29/15 03:06:07 PM
#31052   Simply read what was written in the PMCB Alydyr 01/29/15 03:02:40 PM
#31051   $PMCB A Refresher- The "Cell In A Box" PetePham 01/29/15 03:02:14 PM
#31050   YR 231, avobill 01/29/15 02:59:23 PM
#31049   $PMCB Where Do Human Trials Start? PetePham 01/29/15 02:48:49 PM
#31048   Exactly! Imo just a fluff piece saying what frosr6 01/29/15 02:47:11 PM
#31047   Your logic escapes me. avobill 01/29/15 02:45:19 PM
#31043   PMCB, stated there might be a study. Alydyr 01/29/15 02:12:40 PM
#31042   MM's just weeding out the temp investors to hispeed 01/29/15 02:10:22 PM
#31040   No question there. It is what they are avobill 01/29/15 01:51:23 PM
#31039   Yes I realize this but still has to frosr6 01/29/15 01:42:37 PM
#31037   Darn right Wendy... Anyone can show me a potential PetePham 01/29/15 01:25:41 PM
#31036   Darn right you are Pete - the first avobill 01/29/15 01:19:19 PM
#31035   J, my sentiments exactly. Right now, we Peacefulwendy 01/29/15 01:18:22 PM
#31034   Well said Bill. I am here with you PetePham 01/29/15 01:11:46 PM
#31033   Hello All, avobill 01/29/15 01:06:13 PM
#31032   We are not developing a new drug. avobill 01/29/15 12:46:04 PM
#31031   Hello Mixer, avobill 01/29/15 12:41:33 PM
#31030   5-7 years to start human trials IF FDA frosr6 01/29/15 12:40:50 PM
#31029   $PMCB PharmaCyte Biotech's Pancreatic Cancer Treatment Named as PetePham 01/29/15 12:20:10 PM
#31028   $PMCB PharmaCyte Biotech's Expanded Follow-up Study on Malignant PetePham 01/29/15 12:18:35 PM
#31027   FDA Grants Orphan Drug Designation to Nuvilex for PetePham 01/29/15 12:14:09 PM
#31026   You do know Ken compensated himself $3,200,000 in LuCo 01/29/15 11:51:00 AM
#31025   This is a biotech, long-term hold. Hunker Peacefulwendy 01/29/15 11:50:52 AM
#31024   sorry that with KW said at this point thenewmixer 01/29/15 11:47:53 AM
#31023   "The first preclinical study by TD2 in the Peacefulwendy 01/29/15 11:45:43 AM
#31022   all I keep reading is everyone is buying thenewmixer 01/29/15 11:37:21 AM
#31021   Let's watch and see Dr. Von Hoff will PetePham 01/29/15 11:34:44 AM
#31020   Beautiful. Good to know there is a yeahright231 01/29/15 11:32:13 AM
#31019   I agree young wolf. Just have to Peacefulwendy 01/29/15 11:31:38 AM
#31018   Unfortunately it can be... Peacefulwendy 01/29/15 11:30:49 AM
#31017   Sorry, I don't post a ton but you got J_Ehrat 01/29/15 11:29:21 AM
#31015   That's right. Busy taking the kids to school. PetePham 01/29/15 11:26:29 AM
#31014   That's great. Too much supporters here. All long PetePham 01/29/15 11:25:11 AM
#31013   The PPS is temporary. I am not Peacefulwendy 01/29/15 11:22:49 AM
#31012   where is KW spending pmcb shareholer money traveling... thenewmixer 01/29/15 11:20:48 AM
#31011   .116 four mm's on the bid now budfoxhub 01/29/15 11:19:03 AM
#31009   Now that .10/share has been hit, everyone here Alydyr 01/29/15 11:18:08 AM
#31008   Nobody's gone. No worries. Long-term hold. Peacefulwendy 01/29/15 11:16:53 AM
#31007   PharmaCyte Biotech's Partner Austrianova Opens New Facilities in PetePham 01/29/15 11:11:02 AM
#31006   HAHAH Baby Aspirin dude... Yeah I am yeahright231 01/29/15 11:04:07 AM
#31005   Pete- none of what you are posing has Traderintx 01/29/15 10:59:34 AM
#31004   Day 1 topic Bio Asia Cell In The Box....Wow B_Free 01/29/15 10:57:54 AM
#31001   $PMCB 5 Big Technical Factors For PMCB 1. PMCB PetePham 01/29/15 10:44:25 AM
#31000   Thank you for your input I have been yeahright231 01/29/15 10:44:01 AM
#30999   I study other bio tech stocks dealing with stanchjojoina 01/29/15 10:35:30 AM